Failing to improve FDA's OTC monograph process would be as disruptive to the industry as failing to capitalize on consumers' growing reliance on the digital marketplace would be for drug firms, say the Consumer Healthcare Products Association chief executive and its board chairman.
During the trade group's executive conference focused on disruptive forces in the industry and marketplace, CHPA President and CEO Scott Melville and board Chairman Patrick Lockwood-Taylor, a Procter & Gamble Co